|
Sign In to gain access to subscriptions and/or personal tools.
|
This version was published on February
1, 2006
Journal of Biomolecular Screening, Vol. 11, No. 1,
65-74 (2006)
DOI: 10.1177/1087057105282959
Development of a Novel Dual CCR5-Dependent and CXCR4-Dependent Cell-Cell Fusion Assay System with Inducible gp160 Expression
Changhua Ji
Roche Palo Alto, 3411 Hillview Avenue, Palo Alto, CA 94304 Changhua.ji{at}roche.com
Jun Zhang
Nick Cammack
Surya Sankuratri
In the current study, a novel coreceptor-specific cell-cell fusion (CCF) assay system is reported. The system possesses the following features: dual CCR5-dependent and CXCR4-dependent CCF assays, all stable cell lines, inducible expression of gp160 to minimize cytotoxicity, robust luciferase reporter, and 384-well format. These assays have been validated using various known HIV entry inhibitors targeting various stages of the HIV entry/fusion process, including fusion inhibitors, gp120 inhibitors, CCR5 antagonists, CCR5 antibodies, and CXCR4 antagonists. IC 50data generated from this assay system were well correlated to that from the antiviral assays. The effects of DMSOon this assay systemwere assessed, and a 2-to 3-fold increase in luciferase activitywas observed in the presence of 0.05% to2% DMSO. Although cell-cell fusion efficiencywas enhanced, no changes in drug response kinetics for entry inhibitors were found in the presence of 0.1% or 0.5% DMSO. This assay system has been successfully used for the identification and characterization of thousands of CCR5 inhibitors.
Key Words: HIV • cell-cell fusion • DMSO • luciferase reporter • entry inhibitor
References
- Lazzarin A: Enfuvirtide: the first HIV fusion inhibitor. Expert Opin Pharmacother2005;6:453-464.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Borkow G, Lapidot A: Multi-targeting the entrance door to block HIV-1. Curr Drug Targets Infect Disord2005;5:3-15.[CrossRef][Medline]
[Order article via Infotrieve]
- Pierson TC, Doms RW, Pohlmann S: Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol2004;14:255-270.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Eckert DM, Kim PS: Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem2001;70:777-810.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Coakley E, Petropoulos CJ, Whitcomb JM: Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis2005;18:9-15.[ISI][Medline]
[Order article via Infotrieve]
- Barber CG: CCR5 antagonists for the treatment of HIV. Curr Opin Investig Drugs2004;5:851-861.[Medline]
[Order article via Infotrieve]
- Wood A, Armour D: The discovery of the CCR5 receptor antagonist, UK-427,857, a newagent for the treatment of HIV infection and AIDS. Prog Med Chem2005;43:239-271.[CrossRef][Medline]
[Order article via Infotrieve]
- Watson C, Jenkinson S, Kazmierski W, Kenakin T: The CCR5receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol2005;67:1268-1282.[Abstract/Free Full Text]
- Jenkinson S, McCoy DC, Kerner SA, Ferris RG, Lawrence WK, Clay WC, et al: Development of a novel high-throughput surrogate assay to measure HIV envelope/CCR5/CD4-mediated viral/cell fusion using BacMam baculovirus technology. J Biomol Screen2003;8:463-470.[Abstract]
- Bradley J, Gill J, Bertelli F, Letafat S, Corbau R, Hayter P, et al: Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/ CD4-mediated HIV virus entry. J Biomol Screen2004;9:516-524.[Abstract]
- Chiba H, Asanuma S, Okamoto M, Inokoshi J, Tanaka H, Fujita K, et al: A simple screening system for anti-HIV drugs: syncytium formation assay using T-cell line tropic and macrophage tropic HIV env expressing cell lines— establishment and validation. J Antibiot (Tokyo)2001;54:818-826.[Medline]
[Order article via Infotrieve]
- Hong YL, Wu LH, Cui M, McMaster G, Hunt SW III, Chung FZ: New reporter cell lines to study macrophage-tropic HIV envelope protein-mediated cell-cell fusion. AIDS Res Hum Retroviruses1999;15:1667-1672.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Bossart KN, Broder CC: Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectors. Methods Mol Biol2004;269:309-332.[Medline]
[Order article via Infotrieve]
- Cavrois M, Neidleman J, Bigos M, Greene WC: Fluorescence resonance energy transfer-based HIV-1 virion fusion assay. Methods Mol Biol 2004;263:333-344.[Medline]
[Order article via Infotrieve]
- Schnierle BS, Stitz J, Bosch V, Nocken F, Merget-Millitzer H, Engelstadter M, et al: Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIVgenerates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA1997;94:8640-8645.[Abstract/Free Full Text]
- Kim YB, Lee MK, Han DP, Cho MW: Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain. AIDS Res Hum Retroviruses2001;17:1715-1724.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Ullrich CK, Groopman JE, Ganju RK: HIV-1 gp120 and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood 2000;96:1438-1442.[Abstract/Free Full Text]
- Langford D, Hurford R, Hashimoto M, Digicaylioglu M, Masliah E: Signalling crosstalk in FGF2-mediated protection of endothelial cells from HIVgp120. BMC Neurosci2005;6:8-8.[CrossRef][Medline]
[Order article via Infotrieve]
- Acquas E, Bachis A, Nosheny RL, Cernak I, Mocchetti I: Human immunodeficiency virus type 1 protein gp120 causes neuronal cell death in the rat brain by activating caspases. Neurotox Res2004;5:605-615.[ISI][Medline]
[Order article via Infotrieve]
- Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen1999;4:67-73.[Abstract]
- Ahkong QF, Fisher D, Tampion W, Lucy JA: Mechanisms of cell fusion. Nature1975;253:194-195.[CrossRef][Medline]
[Order article via Infotrieve]
- Wilairat P, Yuthavong Y, Khungvanlert R: Effect of membrane modification on cell fusion of hen erythrocytes induced by dimethyl sulfoxide. Life Sci 1978;22:1993-1997.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Lineberger JE, Danzeisen R, Hazuda DJ, Simon AJ, Miller MD: Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion. J Virol2002;76:3522-3533.[Abstract/Free Full Text]
- Kamikubo Y, Takaori-Kondo A, Uchiyama T, Hori T: Inhibition of cell growth by conditional expression of kpm, a human homologue of Drosophila warts/lats tumor suppressor. J Biol Chem2003;278:17609-17614.[Abstract/Free Full Text]
- Stebbins MJ, Urlinger S, Byrne G, Bello B, Hillen W, Yin JC: Tetracyclineinducible systems for Drosophila. PNAS2001;98:10775-10780.[Abstract/Free Full Text]
- Pellizzoni L, Baccon J, Rappsilber J, Mann M, Dreyfuss G: Purification of native survival of motor neurons complexes and identification of Gemin6 as a novel component. J Biol Chem2002;277:7540-7545.[Abstract/Free Full Text]
- Hauf S, Waizenegger IC, Peters J-M: Cohesin cleavage by separase required for anaphase and cytokinesis in human cells. Science2001;293:1320-1323.[Abstract/Free Full Text]
- Rachek LI, Grishko VI, Alexeyev MF, Pastukh VV, Le Doux SP, Wilson GL: Endonuclease III and endonuclease VIII conditionally targeted into mitochondria enhance mitochondrial DNA repair and cell survival following oxidative stress. Nucleic Acids Res2004;32:3240-3247.[Abstract/Free Full Text]
- Medina D, Moskowitz N, Khan S, Christopher S, Germino J: Rapid purification of protein complexes from mammalian cells. Nucleic Acids Res 2000;28:E61-E61.
- Hayakawal M, Kitagawa H, Miyazawa K, Kitagawa M, Kikugawa K: The FWD1/ß-TrCP-mediated degradation pathway establishes a ‘turning off switch'of aCdc42 guanine nucleotide exchange factor, FGD1. Genes to Cells 2005;10:241-251.[Abstract/Free Full Text]
- Aung W, Okauchi T, Sato M, Saito T, Nakagawa H, Ishihara H, et al: In-vivo PET imaging of inducible D2R reporter transgene expression using [11C]FLB 457 as reporter probe in living rats. Nucl Med Commun 2005;26:259-268.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Green M, Loewenstein P: Autonomous functional domains of chemically synthesized human immunodeficiency virus Tat trans-activator protein. Cell 1988;55:1179-1188.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Frankel A, Pabo C: Cellular uptake of the Tat protein from human immunodeficiency virus. Cell1988;55:1189-1193.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Ruben S, Perkins A, Purcell R, Joung K, Sia R, Burghoff R, et al: Structural and functional characterization of human immunodeficiency virus tat protein. J Virol1989;63:1-8.[Abstract/Free Full Text]
- Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, et al: Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993;67:277-287.[Abstract/Free Full Text]
- Helland DE, Welles JL, Caputo A, Haseltine WA: Transcellular transactivation by the human immunodeficiency virus type 1 tat protein. J Virol1991;65:4547-4549.[Abstract/Free Full Text]
- Marcuzzi A, Lowy I, Weinberger OK: Transcellular activation of the human immunodeficiency virus type 1 long terminal repeat in T lymphocytes requires CD4-gp120 binding. J Virol1992;66:4536-4539.[Abstract/Free Full Text]
- Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, et al: SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA2001;98:12718-12723.[Abstract/Free Full Text]
- Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, Steensma RW, et al: Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl] 4-[4-[2-methoxy-1(R)-4 (trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl] 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem2004;47:2405-2408.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Macartney MJ, Dorr PK, Smith-Burchnel C, et al: In vitro antiviral profile of UK-427,857, a novel CCR5 antagonist [abstract H-875]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, September 14-17, 2003.
- Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, et al: Spirodiketopiperazine-based CCR5 inhibitor which preserves CCchemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol2004;78:8654-8662.[Abstract/Free Full Text]
- Khurana S, Kennedy M, King LR, Golding H: Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity. J Virol2005;79:6791-6800.[Abstract/Free Full Text]
- Si Z, Madani N, Cox JM, Chruma JJ, Klein JC, Schon A, et al: Smallmolecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci USA 2004;101:5036-5041.[Abstract/Free Full Text]
- De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, De Vreese K, et al: Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994;38:668-674.[Abstract/Free Full Text]
- Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS: Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr2000;25:99-102.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Lackman-Smith, C. Osterling, K. Luckenbaugh, M. Mankowski, B. Snyder, G. Lewis, J. Paull, A. Profy, R. G. Ptak, R. W. Buckheit Jr., et al.
Development of a Comprehensive Human Immunodeficiency Virus Type 1 Screening Algorithm for Discovery and Preclinical Testing of Topical Microbicides
Antimicrob. Agents Chemother.,
May 1, 2008;
52(5):
1768 - 1781.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kondru, J. Zhang, C. Ji, T. Mirzadegan, D. Rotstein, S. Sankuratri, and M. Dioszegi
Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists
Mol. Pharmacol.,
March 1, 2008;
73(3):
789 - 800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Cai and M. Gochin
A Novel Fluorescence Intensity Screening Assay Identifies New Low-Molecular-Weight Inhibitors of the gp41 Coiled-Coil Domain of Human Immunodeficiency Virus Type 1
Antimicrob. Agents Chemother.,
July 1, 2007;
51(7):
2388 - 2395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ji, J. Zhang, M. Dioszegi, S. Chiu, E. Rao, A. deRosier, N. Cammack, M. Brandt, and S. Sankuratri
CCR5 Small-Molecule Antagonists and Monoclonal Antibodies Exert Potent Synergistic Antiviral Effects by Cobinding to the Receptor
Mol. Pharmacol.,
July 1, 2007;
72(1):
18 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zhang, E. Rao, M. Dioszegi, R. Kondru, A. DeRosier, E. Chan, S. Schwoerer, N. Cammack, M. Brandt, S. Sankuratri, et al.
The Second Extracellular Loop of CCR5 Contains the Dominant Epitopes for Highly Potent Anti-Human Immunodeficiency Virus Monoclonal Antibodies
Antimicrob. Agents Chemother.,
April 1, 2007;
51(4):
1386 - 1397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Chan, G. Heilek-Snyder, N. Cammack, S. Sankuratri, and C. Ji
Development of a Moloney Murine Leukemia Virus-Based Pseudotype Anti-HIV Assay Suitable for Accurate and Rapid Evaluation of HIV Entry Inhibitors
J Biomol Screen,
September 1, 2006;
11(6):
652 - 663.
[Abstract]
[PDF]
|
|
|
|
